logo
Financial literacy part of new Manitoba math curriculum aimed at preparing students for adulthood

Financial literacy part of new Manitoba math curriculum aimed at preparing students for adulthood

CBC16-05-2025
Manitoba is adding a new compulsory math curriculum in the hope it will mean better grades, and factor into students being better prepared for both advanced courses and adulthood.
The curriculum for Grade 9 students should equip high school students for the demands of precalculus, chemistry and physics, while giving students more time to master practical, hands-on mathematics, Education Minister Tracy Schmidt said in a news release Friday.
The new course will replace the current one that includes an optional transitional math course, the province's release said. Financial literacy elements will be incorporated throughout the curriculum.
The program will be piloted in select schools starting September 2026, with full implementation throughout the province expected in September 2027.
To further promote financial literacy, the province is also providing $65,000 to the non-profit Canadian Foundation for Economic Education to renew resources for teachers who deliver the new curriculum.
The funding will also offer educators updated tools and resources to integrate financial literacy into English language arts, social studies and mathematics curriculums in grades 4-10, the release states.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ZYUS Life Sciences Announces Closing of Second Tranche of Unit Offering
ZYUS Life Sciences Announces Closing of Second Tranche of Unit Offering

Globe and Mail

time14 minutes ago

  • Globe and Mail

ZYUS Life Sciences Announces Closing of Second Tranche of Unit Offering

SASKATOON, SK , Aug. 15, 2025 /CNW/ - ZYUS Life Sciences Corporation (the " Company") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that, further to its press release dated July 29, 2025, it has closed the second tranche (the " Second Tranche") of its non-brokered private placement (the " Offering") of units of the Company (each a " Unit") for up to CAD $1,000,000 . Under the Second Tranche of the Offering, a further 140,845 Units were issued for aggregate gross proceeds of CAD $100,000 . The aggregate gross proceeds raised in the Second Tranche and first tranche of the Offering (which closed on July 29, 2025) (the " First Tranche") is approximately $0.42 million. The Company has issued a total of 591,126 Units each priced at $0.71 per Unit in the First Tranche and the Second Tranche. Each Unit consists of one common share of the Company (a " Common Share") and one Common Share purchase warrant (each Common Share purchase warrant, a " Warrant"), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms (the " Acceleration Provision"). In accordance with the Acceleration Provision, if the volume-weighted average trading price of the Common Shares is greater than $3.00 for a period of 5 consecutive trading days on the TSX Venture Exchange (the " TSXV"), the Company will have the right to accelerate the expiry date of the Warrants. Proceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring November 30, 2025 , and all securities issued under the Second Tranche of the Offering are subject to a hold period expiring December 16, 2025 , in accordance with applicable securities laws and the policies of the TSXV. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, receipt of TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, obtain TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Stellantis lays off 'small number' of workers in Windsor as company cuts back on EV muscle car
Stellantis lays off 'small number' of workers in Windsor as company cuts back on EV muscle car

CBC

time31 minutes ago

  • CBC

Stellantis lays off 'small number' of workers in Windsor as company cuts back on EV muscle car

Stellantis is laying off workers at its assembly plant in Windsor, Ont., as the company shifts away from its electric muscle car. "A small number" of workers received layoff notices Friday, according to Stellantis spokesperson LouAnn Gosselin. "The layoffs are based on seniority and are a result of regular volume adjustments at the plant," Gosselin said. The company would not confirm the number of impacted employees. The union representing the plant's workers did not respond to a request for comment. The news comes on the last day of work before the plant's regular summer shutdown. It also comes at a time of heightened anxiety for auto workers in Canada, especially those in Windsor, where the economy relies heavily on the industry. Workers optimistic Employees at the Windsor assembly plant have faced temporary layoffs in recent months as a result of U.S. President Donald Trump's trade war with Canada and levies on the auto sector — though carve-outs for products that comply with CUSMA, the countries' existing trade deal, have softened the blow. The handful of workers who spoke to CBC Friday outside the Windsor assembly plant said they expect workers to be back on the job before long. "Could be a couple weeks," Emanuele Caruana said. "Right now things aren't looking too good, but they're going to be good soon." Dixon Bell described the layoffs as "not good" but said he too believed workers would be brought back eventually. Dave Lumley isn't worried at all, he said, and predicted the workers would be back on the job before Christmas. "It's just temporary," he said. "It's just a small amount. That happens a lot. It comes and goes. It's only 100 people." Lumley attributed the layoffs to changes in Dodge Charger production at the plant. "We have a battery area, and … we're not building batteries," he said. "Everybody wants gas, so they're trying to transition. That's mainly what it is." In May, Stellantis announced that it was postponing production of the Dodge Charger Daytona R/T, the base model of the first-of-their-kind electrified muscle cars, just a year after introducing them with great fanfare. The global automaker has blamed U.S. tariffs for the decision, but the move also followed weak sales amid a dampening EV market. Workers at the Windsor plant assemble both the Chargers and the company's minivan offerings, including the Chrysler Pacifica. Last week, Stellantis unveiled the 2026 Dodge Charger Scat Pack, equipped with an inline-six twin turbo engine, after months of pleading from gear heads to bring back gas-powered versions of the previously popular muscle cars.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store